| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $70.3974 | $2.27B | N/A |
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q4 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4327577-regenxbio-inc-rgnx-ceo-kenneth-mills-on-q4-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Feb 26, 2020 - REGENXBIO, Inc. (NASDAQ:RGNX) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
0
Regenxbio Inc. (RGNX) Q4 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2020/02/26/regenxbio-inc-rgnx-q4-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001
Feb 26, 2020 - RGNX earnings call for the period ending December 31, 2019.
0
Applied Genetic Stock Up on Favorable Eye Therapy Study Data
http://www.zacks.com/stock/news/711529/applied-genetic-stock-up-on-favorable-eye-therapy-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-711529
Jan 10, 2020 - Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
0
SWN, RGNX and CYTK among notable after hours movers
https://seekingalpha.com/news/3526304-swn-rgnx-and-cytk-among-notable-after-hours-movers?utm_source=feed_news_all&utm_medium=referral
Dec 13, 2019 - Gainers: GVA +4.8%. CYTK +3.3%. TEN +3.1%. BRFS +2.1%. SWN +2%.Losers: AUDC -3.8%. CX -2.6%. NK -1.4%. RGNX -1%.
0
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4302900-regenxbio-inc-rgnx-ceo-kenneth-mills-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Nov 05, 2019 - REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
0
Regenxbio Inc. (RGNX) Q3 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/11/05/regenxbio-inc-rgnx-q3-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001
Nov 05, 2019 - RGNX earnings call for the period ending September 30, 2019.
0
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
http://www.zacks.com/stock/news/605253/regenxbio-rgnx-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-605253
Nov 05, 2019 - Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
0
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
http://www.zacks.com/stock/news/565788/ultragenyxs-rare-nda-for-lc-faod-drug-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-565788
Oct 15, 2019 - Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
0
Big Pharma Has Mad Love For These 2 Biotechs
https://www.fool.com/investing/2019/10/11/big-pharma-has-mad-love-for-these-2-biotechs.aspx?source=iedfolrf0000001
Oct 11, 2019 - These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
0
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772
Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
0
Page 1>